AUTHOR INDEX

(P = Proceedings)

ADIGUN, A.Q. *see* AJAYI, A.A.L.
AFFRIME, M.B. *see* KOSOGLOU, T.
AHMAD, A. *see* REN, Z.
AJAYI, A.A.L. & ADIGUN, A.Q. Angioedema and cough in Nigerian patients receiving ACE inhibitors: 81
AKIE, N.E. *see* MASICA, A.L.
ALLEN, M.J., NICHOLS, D.J. & OLIVER, S.D. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing: 247
AMEYAW, M.M. *see* MORSMAN, J.M.
AMOR, A.M. *see* MENÉNDEZ, R.
ANDERSON, B.J., WOOLLARD, G.A. & HOLFORD, N.H.G. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children: 125
ANGUS, B.J., SMITH, M.D., SUPUTTAMONGKOL, Y., MATTIE, H., WALSH, A.L., WUTHIEKANUN, V., CHAOWAGUL, W. & WHITE, N.J. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion *vs* intermittent bolus injection in septicaemic melioidosis: 183
ARDIET, C. *see* FREYER, G.
ARNON, J. *see* BERKOVITCH, M.
AW, M. *see* SAM, W.J.

BABER, N.S. Clinical pharmacology methodology: introduction: 393
BACK, D.J. Commentary: 85
BACK, D.J. *see* KEWN, S.
BÄCKER, A. *see* KRAMER, H.J.
BACKMAN, J.T. *see* NIEMI, M.
BADLEY, A. *see* KHALIQ, Y.
BADLEY, A. *see* KHALIQ, Y.
BAGHERI, H., MICHEL, F., LAPEYRE-MESTRE, M., LAGIER, E., CAMBUS, J.P., VALDIGUIÉ, P. & MONTASTRUC, J.L. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals: 479
BALL, H.A. *see* DREWE, J.
BALOOLAL, S. *see* NEWTON-SAVAGE, F.A.O.
BANI, M., COLANTONI, A., GUILLAUME, M., MACCHI, F., MORONI, G. & PERSIANI, S. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers: 338
BANJAR, W.M.A., GAZZAZ, J., LANGLEY, R.W., BRADSHAW, C.M. & SZABADI, E. Effects of high ambient temperature on parasympathetically mediated cardiovascular reflexes in normal man: 360
BARBHAIYA, R.H. *see* MARATHE, P.H.
BATRA, V.K. *see* KOSOGLOU, T.
BEGLINGER, C. *see* DREWE, J.
BEGLINGER, C. *see* DREWE, J.
BEIJNEN, J.H. *see* VELDKAMP, A.L.
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* VAN KESTEREN, CH.
BERKOVITCH, M., SEGAL-SOCHER, I., GREENBERG, R., BULKOWSHTEIN, M., ARNON, J., MERLOB, P. & OR-NOY, A. First trimester exposure to cefuroxime: a prospective cohort study: 161
BERG, G. *see* HAMILTON, C.
BERNO, E. *see* CANAPARO, R.
BERRY, C. *see* HAMILTON, C.
BHASKER, C.R. *see* ONG, C.E.
BIRKETT, D.J. *see* ONG, C.E.
BISWAS, P. *see* MARTIN, R.M.
BLAZEVICH, A.J. *see* GILL, N.D.
BLICK, S. *see* KIRCHNER, G.I.
BLIN, O. *see* DINGEMANSE, J.
BOCHNER, F. *see* FOSTER, D.J.R.
BOISSEL, J.P. *see* FREYER, G.
BOYCE, M., WARRINGTON, S., JOHNSTON, A. & HARRIS, A. Effect on gastric pH of repeated doses of YF476, a new gastrin antagonist, compared with omeprazole and placebo: 383P
BRACCHI, R.A. *see* NEWTON-SAVAGE, F.A.O.
BRADDOCK, M. *see* LUNNON, M.W.
BRADSHAW, C.M. *see* BANJAR, W.M.A.
BRADSHAW, C.M. *see* PHILLIPS, M.A.
BRAIN, E. *see* VAN KESTEREN, CH.
BRATER, C. *see* MASICA, A.L.
BRETELER, M.M.B. *see* IN'T'VELD, B.A.
BRICKL, R.-S. *see* DREWE, J.
BROCKMÖLLER, J. *see* STOERMER, E.
BROUWERS, J.R.B.J. *see* JANSMAN, F.G.A.
BROWN, K. *see* MINTO, C.
BRÜCKMANN, M. *see* SALBACH, P.B.
BULKOWSHTEIN, M. *see* BERKOVITCH, M.
BULMAN, D. *see* KHALIQ, Y.
BURGGRAAF, J., KEMME, M.J.B., MULLER, L.M., SCHOEMAKER, R.C. & COHEN, A.F. The influence of the hand circulation on the assessment of venous distensibility of the human forearm with venous occlusion plethysmography: 621
BUSS, N. *see* MUIRHEAD, G.J.
BUTLER, J. *see* HAMILTON, C.

CAMBUS, J.P. *see* BAGHERI, H.
CAMERON, D.W. *see* KHALIQ, Y.
CANAPARO, R., CASALE, F., MUNTONI, E., ZARA, G.P., DELLA PEPA, C., BERNO, E., PONS, N., FORNARI, G. & EANDI, M. Plasma erythropoietin levels in patients receiving intensive platinum or non-platinum chemotherapy: 146
CARIGNAN, G. *see* KHALIQ, Y.
CARLIER, H. *see* VELDKAMP, A.L.
CASALE, F. *see* CANAPARO, R.
CAYEN, M.N. *see* KOSOGLOU, T.
CELERMAJER, D.S. *see* RAITAKARI, O.T.
CHADWICK, D., *see* OWEN, A.
CHAN, P., TOMLINSON, B., CHEN, Y.J., LIU, J.C., HSIEH, M.H. & CHENG, J.T. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension: 215
CHAN, S.Y. *see* SAM, W.J.
CHAOWAGUL, W. *see* ANGUS, B.J.
CHARLES, B.G. *see* SAM, W.J.
CHARLETT, A. *see* DOBBS, S.M.
CHEN, C. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children: 135
CHEN, C., VERONESE, L. & YIN, Y. The effects of lamotrigine on the pharmacokinetics of lithium: 193
CHEN, T.L. *see* ZHOU, H.
CHEN, Y.J. *see* CHAN, P.
CHENG, J.T. *see* CHAN, P.
CHIBA, K. *see* KUBOTA, T.
CHLÁDEK, J. *see* GRIM, J.
CHRYSTYN, H. *see* SILKSTONE, V.L.
CLEMES, S.A. *see* REID, K.
COENEN, J.L.L.M. *see* JANSMAN, F.G.A.
COHEN, A.F. *see* BURGGRAAF, J.
COHEN, A.F. *see* ZWAVELING, J.
COLANTONI, A. *see* BANI, M.
CORLETT, S.A. *see* SILKSTONE, V.L.
COULTER, S. *see* ONG, C.E.
COURT-FORTUNE, I. *see* FREYER, G.
CROCKETT, T.R. *see* STRACHAN, F.E.
CUMMINGS, L., DANE, A., RHODES, J., LYNCH, P. & HUGHES, A.M. Diurnal variation in the quantitative EEG in healthy adult volunteers: 21

© 2000 Blackwell Science Ltd

CVITKOVIC, E. *see* VAN KESTEREN, CH.

DALY, A.K. *see* FORD, G.A.
DANE, A. *see* CUMMINGS, L.
DANHOF, M. *see* SWART, E.L.
DANKERT, J. *see* VERMES, A.
DAVIE, A.P. *see* JHUND, P.S.
DE ABAJO, F.J., JICK, H., DERBY, L., JICK, S. & SCHMITZ, S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors: 43
DE BOER, A. *see* MAITLAND-VAN DER ZEE, A.H.
DE BOER, A. *see* VAN DE VIJVER, D.A.M.C.
DEGRAEUWE, P.L.J. *see* STOLK, L.
DE HOON, J.N.J.M., SMITS, P., TROOST, J., STRUIJKER-BOUDIER, H.A.J. & VAN BORTEL, L.M.A.B. Exploring vascular function and structure in migraine patients, 497P
DE KLERK, S., DERKS, M.G.M., SETTELS, J.J., WESSELING, K.H. & VAN BOXTEL, C.J. PK-PD modelling of the effects of terbutaline on total peripheral resistance in healthy human subjects, 492P
DE JONG-VAN DEN BERG, L. *see* SCHIRM, E.
DE NANTEUIL, G. *see* MORAIN, P.
DEN HARTIGH, J. *see* ZWAVELING, J.
DELLA PEPA, C. *see* CANAPARO, R.
DERBY, L. *see* DE ABAJO, F.J.
DERKS, M.G.M. *see* DE KLERK, S.
DE WILDT, S.N., RIVA, L., VINKS, A.A.T.M.M., HOP, W.C.J., VAN DEN ANKER, J.N. & MURRY, D.J. Pharmacokinetics of 1-OH midazolam after intravenous midazolam in pediatric patients, 494P
DINGEMANSE, J, *see* VAN GIERSBERGEN, P.L.M.
DINGEMANSE, J., SOUBROUILLARD, C., PARIS, J., PISANO, P. & BLIN, O. Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D receptor agonist, 488P
DOBBS, R.J. *see* DOBBS, S.M.
DOBBS, S.M., CHARLETT, A., DOBBS, R.J. & WELLER, C. Insights into the natural history of idiopathioc parkinsonism in relation to *Helicobacter pylori* anti-urease antibody titre: 389P
DOGOLO, L.C. *see* VINCENT, J.
DOMINICZAK, A. *see* HAMILTON, C.
DONNELLY, R. *see* MINTO, C.
DOWNIE, P.F. *see* TALWAR, S.
DREWE, J., BALL, H.A., BEGLINGER, C., PENG, B., KEMMLER, A., SCHCHINGER, H. & HAEFELI, W.E. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine: 237
DREWE, J., NARJES, H., HEINZEL, G., BRICKL, R.-S., ROHR, A. & BEGLINGER, C. Absorption of lefradafiban from different sites of the gastrointestinal tract: 69
DUINKER, M. *see* ZWAVELING, J.
DUNN, N.R. *see* MARTIN, R.M.
DYER, K.R. *see* FOSTER, D.J.R.

EANDI, M. *see* CANAPARO, R.
EDWARDS, R.J., SAURIN, A.T., RAKHIT, R.D. & MARBER, M.S. Therapeutic potential of ischaemic preconditioning: 87
EVANS, A.M. *see* PACE, S.

FARRIN, A.J. *see* LOWE, C.J.
FERNÁNDEZ, J.C. *see* MENÉNDEZ, R.
FIELDING, A. *see* MUIRHEAD, G.J.
FILE, S.E., FLUCK, E. & LEAHY, A. Nicotine and stress-induced mood changes in female and male non-smokers: 384P
FILE, S.E. *see* FLUCK, E.
FINLAY, I. *see* HILLIER, S.L.
FLOTEN, S. *see* REN, Z.
FLUCK, E., FILE, S.E. & RYMER, J. Ten years of hormone replacement therapy and performance in tasks associated with frontal lobe function: 384P
FLUCK, E. *see* FILE, S.E.
FORD, G.A., WOOD, S.M. & DALY, A.K. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system: 77
FORNARI, G. *see* CANAPARO, R.
FORREST, A.R.W. *see* WILLIAMSON, R.V.
FORSYTH, J.T., GRÜNEWALD, R.A., ROSTAMI-HODJEGAN, A., LENNARD, M.S., SAGAR, H.J. & TUCKER, G.T. Parkinson's disease and CYP1A2 activity: 303
FOSTER, B. *see* KHALIQ, Y.
FOSTER, D.J.R., SOMOGYI, A.A., DYER, K.R., WHITE, J.M. & BOCHNER, F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients: 427
FOULDS, G. *see* VINCENT, J.
FRANZKE, A. *see* KIRCHNER, G.I.
FREEMANTLE, S. *see* MARTIN, R.M.
FREYER, G., TRANCHAND, B., LIGNEAU, B., ARDIET, C., SOUQUET, P.J., COURT-FORTUNE, I., RIOU, R., REBATTU, P., BOISSEL, J.P., TRILLET-LENOIR, V. & GIRARD, P. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study: 315
FRIEDMAN, H.L. *see* VINCENT, J.
FRÖLICH, J.C. *see* TROOST, R.
FURNARY, A. *see* REN, Z.
FYKE, K. *see* KHALIQ, Y.

GALLICANO, K. *see* KHALIQ, Y.
GALLICANO, K. *see* KHALIQ, Y.
GALLOWAY, J.H. *see* WILLIAMSON, R.V.
GATELY, H. *see* REN, Z.
GAZZARD, B. *see* VELDKAMP, A.I.
GEBBEN, H. *see* SCHIRM, E.
GEORGE, C.F., PEVELER, R.C., HEILIGER, S. & THOMPSON, C. Compliance with tricyclic antidepressants: the value of four different methods of assessment: 166
GILL, N.D., SHIELD, A., BLAZEVICH, A.J., ZHOU, S. & WEATHERBY, R.P. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes: 205
GIRARD, P. *see* FREYER, G.
GITHANG'A, J. *see* MORSMAN, J.M.
GONZÁLEZ, R.M. *see* MENÉNDEZ, R.
GRAY, G.A. *see* STRACHAN, F.E.
GREENBERG, R. *see* BERKOVITCH, M.
GREENE, D.S. *see* MARATHE, P.H.
GRIM, J., CHLÁDEK, J., MARTÍNOVÁ, J., ŠIMKOVÁ, M., VANECKOVÁ, J., KOUDELKOUVA, V. Pharmacokinetics (PK) and pharmacodynamics (PD) of low dose methotrexate (LDMTX) in the treatment of psoriasis: 390P
GROENEVELD, A. B. J. *see* SWART, E.L.
GROULS, R.J.E., MATHER, L.E., HORSTEN, H.H.M. & GU, X-Q. Diffusion of R- and S-bupivacaine in human dura-arachnoid, 494P
GRÜNEWALD, R.A. *see* FORSYTH, J.T.
GU, X-Q. *see* GROULS, R.J.E.
GUCHELAAR, H.-J. *see* VERMES, A.
GUEZ, D. *see* MORAIN, P.
GUILLAUME, M. *see* BANI, M.
GUZMAN, C. *see* VAN KESTEREN, CH.GAZZAZ, J. *see* BANJAR, W.M.A.

HACKETT, L.P. *see* RAMPONO, J.
HAEFELI, W.E. *see* DREWE, J.
HAMILTON, C., BERRY, C., BERG, G., BUTLER, J., PATHI, V., McINTOSH, L., DOMINICZAK, A. & REID, J.L. Vasorelaxant properties of human isolated radial arteries: comparison with internal mammary artery: 390P
HALL, G.L. *see* WILDHABER, J.H.
HALL, S.D. *see* MASICA, A.L.
HARA, H. *see* KUBOTA, T.

HARRIS. A. *see* BOYCE, M.
HARRIS, M. *see* VELDKAMP, A.L.
HARRIS, S.I. *see* VINCENT, J.
HARRY, F. *see* THOMPSON J.P.
HASHIMOTO, S., YAMAUCHI, E., KOBAYASHI, A., SHIGEMI, K., TSURUTA, H., YAMASHITA, T. & TANAKA, Y. The pharmacokinetics of trinitroglycerin and its metabolites in patients with chronic stable angina: 373
HE, G.W. *see* REN, Z.
HEIDET, V. *see* MORAIN, P.
HEILIGER, S. *see* GEORGE, C.F.
HEINZEL, G. *see* DREWE, J.
HEINZEL, G. *see* TÜRCK, D.
HILLEBRAND, M.J.X. *see* VAN KESTEREN, CH.
HILLIER, S.L., NEWTON-SAVAGE, F.A.O., HUGHES, J., ROUTLEDGE, P.A. & FINLAY, I. Management of cancer-associated pain in general practice: a case-scenario-based distance-learning approach: 386P
HO, P.C. *see* SAM, W.J.
HOFMAN, A. *see* IN'T'VELD, B.A.
HOGGARD, P.G. *see* KEWN, S.
HOLFORD, N.H.G. *see* ANDERSON, B.J.
HOP, W.C.J. *see* DE WILDT, S.N.
HORSTEN, H.H.M. *see* GROULS, R.J.E.
HOTELMANS, R.M.W. *see* VELDKAMP, A.L.
HOUGHTON, J.E. *see* ROUTLEDGE, P.A.
HOUSE, F. *see* REID, K.
HSIEH, M.H. *see* CHAN, P.
HUDSON, J. *see* LOWE, C.J.
HUGHES, A.M. *see* CUMMINGS, L.
HUGHES, J. *see* HILLIER, S.L.
HUITEMA, A.D.R., MATHOT, R.A.A., TIBBEN, M.M., SCHELLENS, J.H.M., RODENHUIS, S. & BEIJNEN, J.H. A mechanism based pharmacokinetic model for the interaction between thiotepa and cyclophosphamide, 496P
HUTCHINGS, A.D. *see* ROUTLEDGE, P.A.
HUTCHINGS, A.D. *see* THOMPSON, J.P.
HUTMAN, W. *see* VELDKAMP, A.L.

ILETT, K.F. *see* RAMPONO, J.
INDALO, A. *see* MORSMAN, J.M.
IN'T'VELD, B.A., RUITENBERG, A., LAUNER, L.J., HOFMAN, A., BRETELER, M.M.B. & STRICKER, B.H.CH. NSAIDs in Alzheimer's disease and dementia, 495P

JACKSON, C.M. *see* LIPWORTH, B.J.
JACOBSEN, W. *see* KIRCHNER, G.I.
JAMALI, F. *see* MAYO, P.R.
JANSEN, H.M. *see* VAN VEEN, A.
JANSEN, P. A. F. *see* VAN DE VIJVER, D.A.M.C.
JANSMAN, F.G.A., COENEN, J.L.L.M. & BROUWERS, J.R.B.J. Predictive value of the area under the curve concentration-time curve (AUC) in blood and in saliva for the toxicity of 5-fluorouracil (5-FU)/folinic acid in the treatment of colorectal cancer, 497P
JHUND, P.S., MCMURRAY, J.J.V. & DAVIE, A.P. The acute vascular effect of frusemide in heart failure: 9
JICK, H. *see* DE ABAJO, F.J.
JICK, S. *see* DE ABAJO, F.J.
JIMÉNEZ, S. *see* MENÉNDEZ, R.
JIMENO, J.M. *see* VAN KESTEREN, CH.
JOCHEMSEN, R. *see* MORAIN, P.
JOHNSON, M.A. *see* KEWN, S.
JOHNSTON, A. *see* BOYCE, M.
JONES, D.R. *see* MASICA, A.L.
JONKERS, R.E. *see* VAN VEEN, A.

KALAFSKY, G. *see* ZHOU, H.
KANAMARU, M. *see* UEMATSU, T.
KAWANO, Y. *see* MINAMI, J.
KEMME, M.J.B. *see* BURGGRAAF, J.
KEMMLER, A. *see* DREWE, J.
KEWN, S., HOGGARD, P.G., SALES, S.D., JOHNSON, M.A. & BACK, D.J. The intracellular activation of lamivudine (3TC) and determination of 2′-deoxycytidine-5′-triphosphate (DCTP) pools in the presence and absence of various drugs in HepG2 cells: 597
KHALIQ, Y., GALLICANO, K., LEGER, R., FOSTER, B. & BADLEY, A. A drug interaction between fusidic acid and a combination of ritonavir and saquinavir: 82
KHALIQ, Y., GALLICANO, K., SEGUIN, I., FYKE, K., CARIGNAN, G., BULMAN, D., BADLEY, A. & CAMERON, D.W. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease: 108
KIRCHNER, G.I., WINKLER, M., MUELLER, L., VIDAL, C., JACOBSEN, W., FRANZKE, A., WAGNER, S., BLICK, S., MANNS, M.P. & SEWING, K.-F. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD: 449
KIVISTÖ, K.T. *see* NIEMI, M.
KIVISTÖ, K.T. *see* PALOVAARA, S.
KLEINERMANS, D *see* MUIRHEAD, G.J.
KLUNGEL, O.H. *see* MAITLAND-VAN DER ZEE, A.H.
KOBAYASHI, A. *see* HASHIMOTO, S.
KOHAN, R. *see* RAMPONO, J.
KOHNO, K. *see* UEMATSU, T.
KOSOGLOU, T., SALFI, M., LIM, J.M., BATRA, V.K., CAYEN, M.N. & AFFRIME, M.B. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine: 581
KOUDELKOUVA, V. *see* GRIM, J.
KOZAWA, O. *see* UEMATSU, T.
KRAMER, H.J., UHL, W., LADSTETTER, B. & BÄCKER, A. Influence of asimadoline, a new κ-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man: 227
KREUZER, J. *see* SALBACH, P.B.
KRISTENSEN, J.H. *see* RAMPONO, J.
KÜBLER, W. *see* SALBACH, P.B.
KUBOTA, T., YAMAURA, Y., OHKAWA, N., HARA, H. & CHIBA, K. Frequencies of *CYP2D6* mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different *CYP2D6* genotypes: 31
KWAKKELSTEIN, M.O. *see* VELDKAMP, A.L.

LADSTETTER, B. *see* KRAMER, H.J.
LAGIER, E. *see* BAGHERI, H.
LAINE, K. *see* PALOVAARA, S.
LAM, E. *see* THOMPSON, J.P.
LANG, D.H. & RETTIE, A.E. *In vitro* evaluation of potential *in vivo* probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms: 311
LANGE, J.M.A. *see* VELDKAMP, A.L.
LANGLEY, R.W. *see* BANJAR, W.M.A.
LAPEYRE-MESTRE, M. *see* BAGHERI, H.
LAU, H. *see* ZHOU, H.
LAUNER, L.J. *see* IN'T'VELD, B.A.
LEAHY, A. *see* FILE, S.E.
LEE, A.F.C., MCFARLANE, L.C. & STRUTHERS, A.D. Ovarian hormones in man: their effects on resting vascular tone, angiotensin converting enzyme activity and angiotensin II-induced vasoconstriction: 73
LEGER, R. *see* KHALIQ, Y.
LENNARD, M.S. *see* FORSYTH, J.T.
LEUFKENS, H.G.M. *see* MAITLAND-VAN DER ZEE, A.H.
LI, B. *see* MINTO, C.
LIGNEAU, B. *see* FREYER, G.
LIM, J.M. *see* KOSOGLOU, T.
LIM, S.M. *see* SAM, W.J.
LINNET, K. *see* OLESEN, O.V.

LIPWORTH, B.J. & JACKSON, C.M. Influences on plasma cortisol of different formulations of beclomethasone dipropionate: 381
LIU, J.C. *see* CHAN, P.
LIU, M. *see* REN, Z.
LONGO, A. *see* PACE, S.
LOOAREESUWAN, S. *see* OOSTERHUIS, B.
LOPEZ-LAZARO, L. *see* VAN KESTEREN, CH.
LOWE, C.J., RAYNOR, D.K., PURVIS, J., FARRIN, A.J. & HUDSON, J. Effects of a medicine review and education programme for older people in general practice: 172
LUGT, CH.B. *see* OOSTERHUIS, B.
LUIK, G. *see* TÜRCK, D.
LUNNON, M.W & BRADDOCK, M. The impact of molecular medicine upon early cardiovascular drug development: 1
LUSCOMBE, D.K. *see* TREMLETT, H.L.
LYNCH, P. *see* CUMMINGS, L.

MACCHI, F. *see* BANI, M.
MACDONALD, T.M. *see* MCMAHON, A.D.
MAITLAND-VAN DER ZEE, A.H., KLUNGEL, O.H., SEIDELL, J.C., LEUFKENS, H.G.M. & DE BOER, A. The association between antihypertensive drug therapies and plasma lipid levels in the general population, 492P
MANN, R.D. *see* MARTIN, R.M.
MANNINEN, P. *see* PALOVAARA, S.
MANNS, M.P. *see* KIRCHNER, G.I.
MARATHE, P.H., WEN, Y., NORTON, J., GREENE, D.S., BARBHAIYA, R.H. & WILDING, I.R. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption: 325
MARBER, M.S. *see* EDWARDS, R.J.
MARINO, M. *see* ZHOU, H.
MARSHALL, R.W. *see* THOMPSON J.P.
MARTIN, R.M., BISWAS, P. & MANN, R.D. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19 087 patients in general practice in England: cohort study: 35
MARTIN, R.M., DUNN, N.R., FREEMANTLE, S. & SHAKIR, S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies: 366
MARTÍNOVÁ, J. *see* GRIM, J.
MATHER, L.E. *see* GROULS, R.J.E.
MATHOT, R.A. A. *see* VERMES, A.
MATHOT, R.A.A. *see* HUITEMA, A.D.R.
MATHOT, R.A.A. *see* VAN KESTEREN, CH.MAKINO, Y. *see* MINAMI, J.
MÁS, R. *see* MENÉNDEZ, R.
MASICA, A.L., AKIE, N.E., BRATER, C., HALL, S.D. & JONES, D.R. Intravenous diltiazem and CYP3A-mediated metabolism: 273
MATSUNO, H. *see* UEMATSU, T.
MATSUOKA, H. *see* MINAMI, J.
MATTIE, H. *see* ANGUS, B.J.
MAXWELL, S.R.J. & WARING, W.S. *Therapeutics* Drugs used in secondary prevention after myocardial infarction: Case presentation: 405
MAXWELL, S.R.J. & WEBB, D. Research methods in human cardiovascular pharmacology: 395
MAYO, P.R., SKEITH, K., RUSSELL, A.S. & JAMALI, F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis: 605
MCFARLANE, L.C. *see* LEE, A.F.C.
MCGETTIGAN, P. *see* SMITH, E.A.J.
MCINTOSH, L., *see* HAMILTON, C.
MCLEOD, H.L. *see* MORSMAN, J.M.
MCLEOD, J.F. *see* ZHOU, H.
MCMAHON, A.D. & MACDONALD, T.M. Design issues for drug epidemiology: 419
MCMURRAY, J.J.V. *see* JHUND, P.S.
MENÉNDEZ, R., MÁS, R., AMOR, A.M., GONZÁLEZ, R.M., FERNÁNDEZ, J.C., RODEIRO, I., ZAYAS, M. & JIMÉNEZ, S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification *in vitro*: 255
MERLOB, P. *see* BERKOVITCH, M.
MEURS, A.H.F. *see* ZWAVELING, J.
MICHEL, F. *see* BAGHERI, H.
MILLER, T. *see* ZHOU, H.
MILLS, N.L. *see* STRACHAN, F.E.
MINAMI, J., KAWANO, Y., MAKINO, Y., MATSUOKA, H. & TAKISHITA, S. The effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension: 615
MINERS, J.O. *see* ONG, C.E.
MINTO, C., LI, B., TATTAM, B., BROWN, K., SEALE, J.P. & DONNELLY, R. Pharmacokinetics of epimeric budenoside and fluticasone propionate after repeat dose inhilation—intersubject variability in systemic absorption from the lung: 116
MISSET, J.L. *see* VAN KESTEREN, CH.
MONTANER, J.S.C. *see* VELDKAMP, A.I.
MONTASTRUC, J.L. *see* BAGHERI, H.
MORAIN, P., ROBIN, J.L., DE NANTEUIL, G., JOCHEMSEN, R., HEIDET, V. & GUEZ, D. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study: 350
MORGAN, P. *see* OWEN, A.
MORONI, G. *see* BANI, M.
MORSMAN, J.M., SLUDDEN, J., AMEYAW, M.M., GITHANG'A, J., INDALO, A., OFORI-ADJEI, D. & MCLEOD, H.L. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanian populations: 269
MUELLER, L. *see* KIRCHNER, G.I.
MUIRHEAD, G.J., WULFF, M.B., FIELDING, A., KLEINERMANS, D & BUSS, N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir: 99
MULLER, L.M. *see* BURGGRAAF, J.
MUNTONI, E. *see* CANAPARO, R.
MURRY, D.J. *see* DE WILDT, S.N.

NAGASHIMA, S. *see* UEMATSU, T.
NARJES, H. *see* DREWE, J.
NEUVONEN, J.P. *see* PALOVAARA, S.
NEUVONEN, P.J. *see* NIEMI, M.
NEWTON-SAVAGE, F.A.O. *see* HILLIER, S.L.
NEWTON-SAVAGE, F.A.O., BALOOLAL, S., SMAIL, S.A., BRACCHI, R.A. & ROUTLEDGE, P.A. Case-based distance learning in primary-care therapeutics: experience of the welsh medicines resource centre (WEMEREC): 392P
NG, L.L. *see* TALWAR, S.
NICHOLS, D.J. *see* ALLEN, M.J.
NIEMI, M., KIVISTÖ, K.T., BACKMAN, J.T. & NEUVONEN, P.J. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride: 591
NIWA, M. *see* UEMATSU, T.
NORTON, J. *see* MARATHE, P.H.

OFORI-ADJEI, D. *see* MORSMAN, J.M.
OHKAWA, N. *see* KUBOTA, T.
OH-UCHI, M. *see* UEMATSU, T.
OLESEN, O.V. & LINNET, K. Identification of the human cytochrome P450 isoforms mediating the *in vitro N*-dealkylation of perphenazine: 563
OLIVER, S.D. *see* ALLEN, M.J.
ONG, C.-E., COULTER, S., BIRKETT, D.J., BHASKER, C.R. & MINERS, J.O. The xenobiotic inhibitor profile of cytochrome P450ZC8: 573
OOSTERHUIS, B., LOOAREESUWAN, S., VAN LIER, J.J., SMEETS, F.W.M. & LUGT, CH.B. Artemotil (beta-arteether) in Thai children with severe

malaria: efficacy *vs* artemether, pharmacodynamics and pharmacokinetics, 489P
OR-NOY, A. *see* BERKOVITCH, M.
OWEN, A., PIRMOHAMED, M., TETTEY, J., MORGAN, P., CHADWICK, D. & PARK, B.K. Is carbamezapine a substrate for P-glycoprotein?: 387P

PACE, S., LONGO, A., TOON, S., ROLAN, P. & EVANS, A.M. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption: 441
PAECH, M. *see* RAMPONO, J.
PALMER, J.L. *see* REID, K.
PALOVAARA, S., KIVISTÖ, K.T., TAPANAINEN, P., MANNINEN, P., NEUVONEN, J.P. & LAINE, K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation: 333
PARIS, J. *see* DINGEMANSE, J.
PARK, B.K. *see* OWEN, A.
PATHI, V. *see* HAMILTON, C.
PATSALOS, P.N. *see* WILLIAMS, J.
PENG, B. *see* DREWE, J.
PERSIANI, S. *see* BANI, M.
PEVELER, R.C. *see* GEORGE, C.F.
PHILLIPS, M.A., SZABADI, E. & BRADSHAW, C.M. Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels: 65
PIRMOHAMED, M. *see* OWEN, A.
PISANO, P. *see* DINGEMANSE, J.
PONS, N. *see* CANAPARO, R.
PORSIUS, A. J. *see* VAN DE VIJVER, D.A.M.C., PORTER, S.J., SOMOGYI, A.A. & WHITE, J.M. Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol: 465
PROOST, J.H. Evaluation of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich and sparse data, 485P
PURVIS, J. *see* LOWE, C.J.

QUAK, S.H. *see* SAM, W.J.

RAKHIT, R.D. *see* EDWARDS, R.J.
RAMPONO, J., KRISTENSEN, J.H., HACKETT, L.P., PAECH, M., KOHAN, R. & ILETT, K.F. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants: 263
RAITAKARI, O.T. & CELERMAJER, D.S. Flow-mediated dilatation: 397
RAYNOR, D.K. *see* LOWE, C.J.
REBATTU, P. *see* FREYER, G.
REID, J.L. *see* HAMILTON, C.
REID, K., PALMER, J.L., WRIGHT, R.J., CLEMES, S.A., TROAKES, C., SOMAL, H.S., HOUSE, F. & STOTT, J.R.R. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT_3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man: 61
REISS, P. *see* VELDKAMP, A.I.
REN, Z., LIU, M., FURNARY, A., FLOTEN, S., GATELY, H., SWANSON, J., AHMAD, A. & HE, G.W. Effects of potassium channel opener KRN4884 on human conduit arteries used as coronary bypass grafts: 154
RETTIE, A.E. *see* LANG, D.H.
RHODES, J. *see* CUMMINGS, L.
RIOU, R. *see* FREYER, G.
RIVA, L. *see* DE WILDT, S.N.
ROBIN, J.L. *see* MORAIN, P.
RODEIRO, I. *see* MENÉNDEZ, R.
RODENHUIS, S. *see* HUITEMA, A.D.R.
ROHR, A. *see* DREWE, J.
ROJCZYK, S. *see* TROOST, R.
ROLAN, P. *see* PACE, S.
ROOS, R.A.C. *see* VAN DE VIJVER, D.A.M.C.
ROOTS, I. *see* STOERMER, E.
ROSING, H. *see* VAN KESTEREN, CH.
ROSTAMI-HODJEGAN, A. *see* FORSYTH, J.T.
ROUTLEDGE, P.A. *see* HILLIER, S.L.
ROUTLEDGE, P.A. *see* NEWTON-SAVAGE, F.A.O.
ROUTLEDGE, P.A. *see* THOMPSON, J.P.
ROUTLEDGE, P.A., WOODS, F.A., HOUGHTON, J.E., HUTCHINGS, A.D. & THOMPSON, J.P. CSM Wales: 16 years' experience as a regional pharmacovigilance centre: 391P
RUITENBERG, A. *see* IN'T'VELD, B.A.RUSSELL, A.S. *see* MAYO, P.R.
RUYS-DUDOK VAN HEEL, I. *see* ZWAVELING, J.RYMER, J. *see* FLUCK, E.

SALES, S.D. *see* KEWN, S.
SAGAR, H.J. *see* FORSYTH, J.T.
SALBACH, P.B., BRÜCKMANN, M., TUROVETS, O., KREUZER, J., KBLER, W. & WALTER-SACK, I. Heparin-mediated selective release of hepatocyte growth factor in humans: 221
SALFI, M. *see* KOSOGLOU, T.
SAM, W.J., AW, M., QUAK, S.H., LIM, S.M., CHARLES, B.G., CHAN, S.Y. & HO, P.C. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients: 531
SAUER, P. *see* SCHIRM, E.
SAURIN, A.T. *see* EDWARDS, R.J.
SCHCHINGER, H. *see* DREWE, J.
SCHELLENS, J.H.M. *see* HUITEMA, A.D.R.
SCHELLENS, J.H.M. *see* VAN KESTEREN, CH.
SCHIRM, E., VAN DEN BERG, P., GEBBEN, H., SAUER, P. & DE JONG-VAN DEN BERG, L. Drug use of children in the community assessed through pharmacy dispensing data: 473
SCHMITZ, S. *see* DE ABAJO, F.J.
SCHOEMAKER, H.C. *see* ZWAVELING, J.
SCHOEMAKER, R.C. *see* BURGGRAAF, J.
SCHWEDHELM, E. *see* TROOST, R.
SEALE, J.P. *see* MINTO, C.
SEIDELL, J.C. *see* MAITLAND-VAN DER ZEE, A.H.
SEGAL-SOCHER, I. *see* BERKOVITCH, M.
SEGUIN, I. *see* KHALIQ, Y.
SETTELS, J.J. *see* DE KLERK, S.
SEWING, K.-F. *see* KIRCHNER, G.I.
SHAKIR, S. *see* MARTIN, R.M.
SHERIDAN, D.J. Drug-induced proarrhythmic effects: assessment of changes in QT interval: 297
SHIELD, A. *see* GILL, N.D.
SHIGEMI, K. *see* HASHIMOTO, S.
SHORE, A.C. Capillaroscopy and the measurement of capillary pressure: 501
SILKSTONE, V.L., TOMLINSON, H.S., CORLETT, S.A. & CHRYSTYN, H. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged: 281
ŠIMKOVÁ, M. *see* GRIM, J.
SKEITH, K. *see* MAYO, P.R.
SLUDDEN, J. *see* MORSMAN, J.M.
SMAIL, S.A. *see* NEWTON-SAVAGE, F.A.O.
SMEETS, F.W.M. *see* OOSTERHUIS, B.
SMITH, A.J. & MCGETTIGAN, P. Quality use of medicines in the community: the Australian experience, 515
SMITH, M.D. *see* ANGUS, B.J.
SMITS, P. *see* DE HOON, J.N.J.M.
SOMAL, H.S. *see* REID, K.
SOMOGYI, A.A. *see* FOSTER, D.J.R.
SOMOGYI, A.A. *see* PORTER, S.J.
SOUBROUILLARD, C. *see* DINGEMANSE, J.
SOUQUET, P.J. *see* FREYER, G.
SQUIRE, I.B. *see* TALWAR, S.
STÖRMER, E., ROOTS, I. & BROCKMÖLLER, J. Benzydamine-*N*-oxidation as anindex reaction reflecting FMO activity in human liver microsomes and impact of *FMO3* polymorphisms on enzyme activity: 553

STOLK, L. & DEGRAEUWE, P.L.J. Gentamicin pharmacokinetics in preterm infants of less than 30 weeks gestational age at birth: effect of postnatal age, 498P
STOTT, J.R.R. *see* REID, K.
STRACHAN, F.E., CROCKETT, T.R., MILLS, N.L., GRAY, G.A. & WEBB, D.J. Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and capacitance vessels *in vivo*: 27
STRICKER, B.H.CH. *see* IN'T'VELD, B.A.
STRUIJKER-BOUDIER, H.A.J. *see* DE HOON, J.N.J.M.
STRUTHERS, A.D. *see* LEE, A.F.C.
SUMMERS, Q.A. *see* WILDHABER, J.H.
SUPUTTAMONGKOL, Y. *see* ANGUS, B.J.
SWANSON, J. *see* REN, Z.
SWART, E. L., VAN DER HOVEN, B., GROENEVELD. A. B. J., TOUW, D. J. & DANHOF, M. Correlation between mdazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers, 487P
SZABADI, E. *see* BANJAR, W.M.A.
SZABADI, E. *see* PHILLIPS, M.A.

TAKISHITA, S. *see* MINAMI, J.
TALWAR, S., DOWNIE, P.F., NG, L.L. & SQUIRE, I.B. Towards a blood test for heart failure: the potential use of circulating natriuretic peptides: 15
TANAKA, Y. *see* HASHIMOTO, S.
TAPANAINEN, P. *see* PALOVAARA, S.
TATTAM, B. *see* MINTO, C.
TEAUME, K. *see* VAN KESTEREN, CH.
TETTEY, J. *see* OWEN, A.
THOMAS, A.M. *see* THOMPSON, J.P.
THOMPSON, C. *see* GEORGE, C.F
THOMPSON, J.P., LAM, E., THOMAS, A.M., HARRY, F., HUTCHINGS, A.D., MARSHALL, R.W. & ROUTLEDGE, P.A. The pharmacokintecs and CNS effects of 10 mg of oral d-9-tetrahydrocannabinol in man: 385P
THOMPSON, J.P. *see* ROUTLEDGE, P.A.
TIBBEN, M.M. *see* HUITEMA, A.D.R.
TOMLINSON, B. *see* CHAN, P.
TOMLINSON, H.S. *see* SILKSTONE, V.L.
TOON, S. *see* PACE, S.
TOUW, D.J. *see* SWART, E.L.
TOUW, D.J., VAN WEISSENBRUCH, M.M. & LAFEBER, H.N. The predictive performance of therapeutic drug monitoring (TDM) of amikacin in neonates using an early single determination of the serum concentration together with a population model, 487P
TRANCHAND, B. *see* FREYER, G.
TREMLETT, H.L., WILES, C.M. & LUSCOMBE, D.K. Nonprescription medicine use in an multiple sclerosis clinic population: 55
TRILLET-LENOIR, V. *see* FREYER, G.
TROAKES, C. *see* REID, K.
TROOST, J. *see* DE HOON, J.N.J.M.
TROOST, R., SCHWEDHELM, E., ROJCZYK, S., TSIKAS, D. & FRÖLICH, J.C. Nebivolol decreases systemic oxidative stress in healthy volunteers: 377
TSIKAS, D. *see* TROOST, R.
TSURUTA, H. *see* HASHIMOTO, S.
TUCKER, G.T. *see* FORSYTH, J.T.
TÜRCK, D., HEINZEL, G. & LUIK, G. Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam: 197
TUROVETS, O. *see* SALBACH, P.B.

UEMATSU, T., KOZAWA, O., MATSUNO, H., NIWA, M., YOSHIKOSHI, H., OH-UCHI, M., KOHNO, K., NAGASHIMA, S. & KANAMARU, M. Pharmacokinetics and tolerability of intravenous infusion of adenosine (SUN Y4001) in healthy volunteers: 178
UHL, W. *see* KRAMER, H.J.

VALDIGUIÉ, P. *see* BAGHERI, H.
VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M.
VAN BOXTEL, C.J. *see* DE KLERK, S.
VAN DE VIJVER, D.A.M.C., ROOS, R.A.C., JANSEN, P.A.F., PORSIUS, A.J. & DE BOER, A. Selective serotonin reuptake inhibitor (SSRI) therapy is associated with an increase in antiparkinsonian drug treatment in patients on levodopa, 486P
VAN DEN ANKER, J.N. *see* DE WILDT, S.N.
VAN DEN BERG, P. *see* SCHIRM, E.
VAN DER HOVEN, B. *see* SWART, E.L.
VAN DER SIJS, I.H. *see* VERMES, A.
VANECKOVÁ, J. *see* GRIM, J.
VAN GIERSBERGEN, P.L.M. & DINGEMANSE, J. Multiple-dose pharmacokinetics and tolerability of IS-159, a new serotonin 1B/1D receptor agonist, 490P
VAN KESTEREN, CH., CVITKOVIC, E., MISSET, J.L., TEAUME, K., JIMENO, J.M., LOPEZ-LAZARO, L., GUZMAN, C., MATHOT, R.A.A., SCHELLENS, J.H.M., BRAIN, E., HILLEBRAND, M.J.X., ROSING, H. & BEIJNEN, J.H. Pharmacokinetics and pharmacodynamics of the novel marine derived agent Ecteinascidin 743 in a phase 1 dose finding study, 489P
VAN LIER, J.J. *see* OOSTERHUIS, B.
VAN VEEN, A., WELLER, F.R., WIERENGA, E.A., JANSEN, H.M. & JONKERS, R.E. Regular use of long-acting β2-adrenoceptor agonists attenuates the bronchoprotective efficacy of short acting β2-adrenoceptor agonists in asthma, 499P
VASEY, P.A. Immunotherapy for renal carcinoma: theoretical basis and current standard of care: 521
VELDKAMP, A.I., HOTELMANS, R.M.W., BEIJNEN, J.H., HARRIS, M., MONTANER, J.S.C., YOULE, M., HUTMAN, W., GAZZARD, B., CARLIER, H., KWAKKELSTEIN, M.O., LANGE, J.M.A. & REISS, P. The pharmacokinetics (PK) of combined once daily nevirapine (NVP) and efavirenz (EFV), 495P
VERMEIJ, P. *see* ZWAVELING, J.
VERMES, A., MATHOT, R.A.A., VAN DER SIJS, I. H., DANKERT, J. & GUCHELAAR, H.-J. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM and NONMEM, 485P
VERONESE, L. *see* CHEN, C.
VIDAL, C. *see* KIRCHNER, G.I.
VINCENT, J., HARRIS, S.I., FOULDS, G., DOGOLO, L.C., WILLAVIZE, S. & FRIEDMAN, H.L. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine: 455
VINKS, A.A.T.M.M. *see* DE WILDT, S.N.

WAGENAAR, L.J., VOORS, A.A., BUIKEMA, J.H., GANSEVOORT, R.T., PINTO, Y.M., DE GRAEFF, P.A. & VAN GILST, W.H. Competitive *vs* non-competitive AT1-receptor antagonists in human vessels, 493P
WAGNER, S. *see* KIRCHNER, G.I.
WALKER, P.D. & WALLEY, T. Feasibility study of multicentre comparison of NHS hospital pharmacy computer data: 48
WALLEY, T. *see* WALKER, P.D.
WALSH, A.L. *see* ANGUS, B.J.
WALTERS, M. Hands-on Guide to Clinical Pharmacology: 382
WALTER-SACK, I. *see* SALBACH, P.B.
WARING, W.S. *see* MAXWELL, S.R.J.
WARRINGTON, S. *see* BOYCE, M.
WATERER, G.W. *see* WILDHABER, J.H.
WEATHERBY, R.P. *see* GILL, N.D.
WEBB, D. *see* MAXWELL, S.R.J.
WEBB, D.J. *see* STRACHAN, F.E.
WELLER, C. *see* DOBBS, S.M.
WELLER, F.R. *see* VAN VEEN, A.
WEN, Y. *see* MARATHE, P.H.
WESSELING, K.H. *see* DE KLERK, S.
WESTPHAL, J.F. Macrolide—induced clinically relevant drug interactions with

cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin: 285
WHITE, J.M. *see* FOSTER, D.J.R.
WHITE, J.M. *see* PORTER, S.J.
WHITE, N.J. *see* ANGUS, B.J.
WIERENGA, E.A. *see* VAN VEEN, A.
WILDHABER, J.H., WATERER, G.W., HALL, G.L. & SUMMERS, Q.A. Reducing electrostatic charge on spacer devices and bronchodilator response: 277
WILDING, I.R. *see* MARATHE, P.H.
WILES, C.M. *see* TREMLETT, H.L.
WILLAVIZE, S. *see* VINCENT, J.
WILLIAMS, J., PATSALOS, P.N. & WILSON, J.F. Relationship between hair and steady-state plasma concentrations of carbamezpine in a compliant in-patient epileptic population: 387P
WILLIAMSON, R.V., GALLOWAY, J.H., YEO, W.W. & FORREST, A.R.W. Relationship between blood dextropropoxyphene and ethanol levels in fatal co-proxamol overdosage: 388P
WILSON, J.F. *see* WILLIAMS, J.
WINKLER, M. *see* KIRCHNER, G.I.
WOOD, S.M. *see* FORD, G.A.
WOODS, F.A. *see* ROUTLEDGE, P.A.
WOOLLARD, G.A. *see* ANDERSON, B.J.
WRIGHT, R.J. *see* REID, K.
WULFF, M.B. *see* MUIRHEAD, G.J.
WUTHIEKANUN, V. *see* ANGUS, B.J.

YAMASHITA, T. *see* HASHIMOTO, S.
YAMAUCHI, E. *see* HASHIMOTO, S.
YAMAURA, Y. *see* KUBOTA, T.
YEO, W.W. *see* WILLIAMSON, R.V.
YIN, Y. *see* CHEN, C.
YOSHIKOSHI, H. *see* UEMATSU, T.
YOULE, M. *see* VELDKAMP, A.L.

ZARA, G.P. *see* CANAPARO, R.
ZAYAS, M. *see* MENÉNDEZ, R.
ZHOU, H., CHEN, T.L., MARINO, M., LAU, H., MILLER, T., KALAFSKY, G. & MCLEOD, J.F. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects: 543
ZHOU, S. *see* GILL, N.D.
ZWAVELING, J., DUINKER, M., RUYS-DUDOK VAN HEEL, I., MEURS, A.H.F., SCHOEMAKER, H.C., COHEN, A.F., DEN HARTIGH, J. & VERMEIJ, P. The pharmacokinetics of a single rectal dose of tramadol in postoperative pediatric patients, 491P

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

Absorption, 325
ACE activity, 73
ACE inhibitors, 81
Acetyl-L-carnitine, 441
Adenosine, 177
Adjunctive therapy, 135
α_2-adrenoceptors, 65
Adverse drug reaction, 35, 366, 479
Allometry, 125
Alzheimer's disease, 495P
Ambulatory blood pressure, 615
Amikacin, 487P
Amlodipine, 455
Amphetamines, 205
Angioedema, 81
Angiogenesis, 221
Angiotensin II type 1 receptor antagonists, 493P
Angiotensin II, 73
Antiarrhythmic, 247
Anticancer chemotherapy, 146
Antidepressants, 166
Antihypertensive therapy, 492P
Antiretroviral protease inhibitors, 99
Anti-urease antibody titre, 389P
Artemether, 489P
Artemotil, 489P
Arteries, 9
Asimadoline, 227
Asthma, 499P
Atrial natriuretic peptide, 227
Autonomic function, 615

β-adrenoceptor antagonists, 377
β_2-adrenoceptor agonists, 499P
Bayesian technique, 485P
Beclamethasone dipropionate, 381
Benzydamine *N*-oxidation, 553
Benzydamine, 311
Biological markers, 338
Brain natriuretic peptide, 15
Bronchodilatation, 205
Bronchodilator response, 277
Budesonide, 116
Bupivacaine, 494P

Caffeine metabolism, 303
Caffeine, 311
Calcitonin gene related peptide, 497P
Calcium antagonist, 615
Calcium channel blockers, 273
Cancer anaemia, 146
Cancer therapy, 146
Cancer-associated pain, 386P
Capillary blood velocity, 501
Capillary density, 501
Caprylocaproyl macrogolglycerides, 488P
Carbamazepine, 387P
Cardiotoxicity, 35
Cardiovascular drug development, 1
Cardiovascular reflexes, 360
Cefuroxime, 161
Children, 135, 473, 491P, 494P
Cholecystectomized, 543
Cilnidipine, 615
Cimetidine, 581
Citalopram, 263
Clinical pharmacist, 172
Clinical pharmacology methodology, 393
Clonidine, 65
Cold pressor, 615
Colorectal cancer, 497P
Comparative bioavailability, 125
Compliance, 166, 215
Computer, 48
Coppe-mediated oxidation, 255
Cost effectiveness, 515
Cough, 81
CSM Wales, 391P
Cyclophosphamide, 496P
Cyclosporin, 449
CYP2C19, 77, 108
CYP2C8, 573
CYP2C9, 591
*CYP2D6*10*, 31
*CYP2D6*14*, 31
CYP2D6, 77
CYP2E1, 303
CYP3A, 273
CYP3A4, 333
CYP450 2C9, 99
CYP450 3A4, 99
Cytochrome P450, 285, 311, 563, 573

Δ-9-tetrahydrocannabinol, 385P
dCTP, 597
Dementia, 495P
Demethylcitalopram, 263
Detergent, 277
Dextromethorphan, 31
Dextropropoxyphene, 388P
Diagnosis, 15
Diarrhoea, 366
Dihydropyrimidine dehydrogenase, 269
Diltiazem, 273
Distance learning, 386P, 392P
Diurnal variation, 21
Dofetilide, 247
Doxorubicin, 315,
Dromotropic response, 605
Drug dependence, 427
Drug epidemiology, 419
Drug interaction, 82
Drug interactions, 82, 273, 285, 573, 597
Drug metabolism, 269, 449
Drug monitoring, 35
Drug use, 473
Drug utilization study, 473
Drug-induced liver injuries, 479
Drugs in sport, 205
Drugs, 55
Dual ACE-NEP inhibitors, 338

Ecteinascidin, 489P
Education, 172
Efavirenz, 495P
Elderly, 172
Electrocardiographic, 581
Electrospray-MS, 449
Electrostatic charge, 277
Enantiomers, 455
Endothelial function, 397
Endothelin, 227
Endothelin-1, 27
Enteral absorption, 69
Ephedrine, 205
Epilepsy, 387P
Ergogenics, 205
ETB receptor agonist, 27
Ethanol, 388P
Ethinyloestradiol, 333
Ethnic variability, 269
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 427
Etoposide, 315
Exercise performance, 205

Fibrinogen receptor antagonist, 69
FK 506, 531
Flavin-containing monooxygenase, 311, 553
Flow-mediated dilatation, 397
Flucytosine, 485P
5-fluorouracil, 269, 497P
Fluticasone propionate, 116
Folinic acid, 497P
Forearm, 621
Formoterol, 499P
Fradafiban, 69
Free water clearance, 227
Frontal lobe function, 384P
Frusemide, 9
Fusidic acid, 81
5-FU therapy, 146

Gamma scintigraphy, 325
Gastric pH, 383P
Gastrin antagonist, 383P
Gastrointestinal activity, 325
Gastrointestinal toxicity, 35
General practice, 172, 366
Gentamicin, 497P
Gestodene, 333
Glimepiride, 591
Grapefruit juice, 455

© 2000 Blackwell Science Ltd

Hair concentration, 387P
Healthy subjects, 221
Healthy volunteers, 65, 177, 237, 255, 338, 377
Heart failure, 9, 15
Heart rate variability, 615
Heart rate, 360, 615
Heat stressor, 360
Helicobacter pylori, 389P
Hepatocyte growth factor, 221
HepG2 cells, 597
Holding chamber, 277
Hormone replacement therapy, 384P
Hospital, 48
5-HT_3 receptor antagonist, 61
Human cardiovascular pharmacology, 395
Human conduit arteries, 154
Human internal mammary artery, 390P
Human liver cytosol, 465
Human liver microsomes, 311, 563
Human milk, 263
Human radial arteries, 390P
Human, 553
Hyoscine, 61
Hypertension, 215

Ifosfamide, 315
IGF-1, 543
Immunotherapy, 521
Infant dose, 263
Inhibition, 465
Interaction, 193, 197, 333, 496P, 591
Intracranial haemorrhage, 43
IS-159, 488P, 490P
Ischaemic preconditioning, 87

Japanese, 31

κ-opioid agonist, 227
Ketoconazole, 581
Kinetics, 465
KRN4884, 154

Laboratory signals, 479
Lamivudine, 597
Lamotrigine, 135, 193
L-carnitine, 441
LDL lipid peroxidation, 255
Lefradafiban, 69
Levodopa, 486P
Lignocaine, 487P
Lipids, 492P
Lithium, 193
Lithium, 197
Liver didease,108
Liver toxicity, 35
Liver transplantation, 531
Loratidine, 581
Losartan, 493P
Lovastatin, 273
Low molecular weight heparin, 221

Macrolides, 285
Macrophage-mediated oxidation, 255
Malaria, 489P
Medication compliance, 172
Medication knowledge, 172
Medicine usage, 55
Medroxyprogesterone, 73
MEGX test, 487P
Meloxicam, 35, 197
Memory enhancer, 350
Metabolism, 427
Metabolite, 177
Metabolites, 449
Metformin, 325
Methadone, 427
Methotrexate, 390P
Microencapsulated octreotide acetate, 543
Midazolam, 333, 487P, 494P
Migraine, 497P
Milk/plasma ratio, 263
Modelling, 492P
Molecular medicine, 1
Mood changes, 384P
Morphine, 237
Morphine-3-glucuronide, 237
Morphine-6-glucuronide, 237
Motion sickness, 61
Multidrug resistance, 237
Multiple sclerosis, 55
Muscle activation, 205
Myocardial infarction, 405

6β-naltrexol, 465
Naltrexone, 465
N-dealkylation, 563
Nelfinavir, 108
Neonates, 487P
Nephrotoxicity, 35
Nevirapine, 495P
Nicotine, 384P
Nitric oxide, 497P
NK_1 receptor antagonist, 61
Nonlinear pharmacokinetics, 441
NONMEM, 125, 531
Nonprescription, 55
Non-steroidal anti-inflammatory agent, 35
Noradrenaline, 205
N-oxide, 311
NSAIDs, 197, 495P

Oestradiol, 73
Omeprazole, 383P
Overdose, 388P
Over-the-counter, 55
Oxidative stress, 377

Paediatrics, 125, 473, 531
Paracetamol, 125
Parkinson's disease, 303, 389P, 486P
Performance tasks, 384P
Perphenazine, 563
P-glycoprotein, 237, 387P
Pharmacodynamics, 247, 338, 350, 390P, 489P
Pharmacoeconomics, 515
Pharmacoepidemiology, 35, 419, 473
Pharmacokinetic interactions, 99
Pharmacokinetics, 108, 177, 193, 197, 247, 338, 385P, 390P, 427, 449, 455, 485P, 487P, 489P, 490P, 491P, 494P, 495P, 496P, 498P
Pharmacovigilance, 77, 366, 391P
Pharmacy data, 473
Pharmacy, 48
Phase 1 study, 338
Phenotyping, 553
Phosphorylation, 597
Physiological finger tremor, 360
Plasma concentration, 373, 387P
Plasma cortisol, 381
Plasma erythropoietin, 146
Platinum therapy, 146
Plethysmography, 621
Policosanol, 255
Population model, 487P
Population pharmacodynamics, 543
Population pharmacokinetics, 116, 125, 135, 315, 485P, 531, 543
Potassium channel opener, 154
Pregnancy, 161
Prescribing, 48
Prescription event monitoring, 35, 366
Preterm infants, 498P
Primary care, 392P
Prolonged inhalation, 281
Prolyl endopeptidase inhibitor, 350
Propranolol, 360
Protein binding, 427
Proton pump inhibitors, 366
Psoriasis, 390P
Pupillometry, 65

QT interval, 297
QTc interval, 247
Quantitative EEG, 21

Relative lung bioavailability, 281
Renal carcinoma, 521
Renal clearance, 441
Renal function, 227
Renal metabolism, 441
Repolarization, 581
Rheumatoid arthritis, 605
Rich data, 485P
Rifampicin, 591
Ritonavir, 81, 99

Safety and tolerability, 338
Salbutamol, 281
Salmeterol, 499P
Saquinavir, 81, 99
Sarafotoxin S6c, 27
SDZ PSC 833, 237
SDZ RAD, 449
Secondary prevention, 405
Selective serotonin reuptake inhibitors, 43, 486P
Serotonin 1B/1D receptor agonist, 488P
Serotonin, 43
Sildenafil citrate, 99
Sildenafil, 85
Skin microcirculation, 501

© 2000 Blackwell Science Ltd

Small cell lung cancer, 315
Spacer, 277
Sparse data, 485P
Standard heparin, 221
Stereoselectivity, 427
Stevioside, 215
Stimulants, 205
Stress, 384P
Study design, 419
Sympathomimetics, 205

Tacrolimus, 531
Teratogenicity, 161
Terbutaline, 492P
Terodiline, 77
Therapeutic drug monitoring, 449, 487P
Thiotepa, 496P
Tolerability, 177, 490P
Total peripheral resistance, 492P
Tramadol, 491P
Transdermal tape system, 373
Trinitroglycerin, 373
Tubular reabsorption, 441

Ultrasound, 397
Underreporting rate, 479
Urinary excretion, 281

Valsartan, 493P
Valspodar, 237
Vascular capacitance, 621
Vascular function, 497P
Vasoconstriction, 27
Vasopressin, 227
Vasorelaxation, 154
Veins, 9, 621
Verapamil, 605
Volunteers, 21

WEMEREC, 392P

YF476, 383
Yohimbine, 65

Z13752A, 338